Should I buy or sell Tango Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNGX shares. View TNGX analyst ratings or view top-rated stocks .

What is Tango Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 1 year price objectives for Tango Therapeutics' shares. Their TNGX share price targets range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next year. This suggests a possible upside of 106.2% from the stock's current price. View analysts price targets for TNGX or view top-rated stocks among Wall Street analysts .

How have TNGX shares performed in 2023?

Tango Therapeutics' stock was trading at $7.25 on January 1st, 2023. Since then, TNGX shares have increased by 7.0% and is now trading at $7.76. View the best growth stocks for 2023 here .

When is Tango Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024. View our TNGX earnings forecast .

How were Tango Therapeutics' earnings last quarter?

Tango Therapeutics, Inc. (NASDAQ:TNGX) posted its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.11. The firm earned $10.73 million during the quarter, compared to the consensus estimate of $8.05 million. Tango Therapeutics had a negative net margin of 266.73% and a negative trailing twelve-month return on equity of 41.41%.

What ETF holds Tango Therapeutics' stock ?

Range Cancer Therapeutics ETF holds 34,808 shares of TNGX stock, representing 1.18% of its portfolio.

Who are Tango Therapeutics' major shareholders?

Tango Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (11.42%), Adage Capital Partners GP L.L.C. (1.72%), Deerfield Management Company L.P. Series C (0.78%), Invesco Ltd. (0.76%), Northern Trust Corp (0.39%) and Charles Schwab Investment Management Inc. (0.36%). Insiders that own company stock include Adam Crystal and Boxer Capital, Llc. View institutional ownership trends .

How do I buy shares of Tango Therapeutics?

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Tango Therapeutics Stock Price, News & Analysis (NASDAQ:TNGX)

$7.76

+0.16 (+2.11%)

(As of 12/1/2023 ET)

Compare

Today's Range: $7.44
▼
$7.87
50-Day Range: $6.52
▼
$12.01
52-Week Range: $2.47
▼
$13.03

Volume: 452,879 shs
Average Volume: 625,197 shs
Market Capitalization: $791.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.00

Tango Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 106.2% Upside
$16.00 Price Target
Short Interest: Bearish
18.39% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$8.72 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.05) to ($1.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

629th out of 957 stocks

Pharmaceutical Preparations Industry

298th out of 443 stocks

3.5

Analyst's Opinion

Consensus Rating
Tango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.00, Tango Therapeutics has a forecasted upside of 106.2% from its current price of $7.76.
Amount of Analyst Coverage
Tango Therapeutics has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
18.39% of the float of Tango Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Tango Therapeutics has a short interest ratio ("days to cover") of 7.7.
Change versus previous month
Short interest in Tango Therapeutics has recently increased by 10.66%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tango Therapeutics does not currently pay a dividend.
Dividend Growth
Tango Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TNGX.

2.4

News and Social Media Coverage

News Sentiment
Tango Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Tango Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for TNGX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tango Therapeutics insiders have bought 382.51% more of their company's stock than they have sold. Specifically, they have bought $8,722,500.00 in company stock and sold $1,807,734.00 in company stock.
Percentage Held by Insiders
Only 6.20% of the stock of Tango Therapeutics is held by insiders.
Percentage Held by Institutions
78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.05) to ($1.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tango Therapeutics is -6.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tango Therapeutics is -6.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tango Therapeutics has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Tango Therapeutics Stock (NASDAQ:TNGX)

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

TNGX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TNGX Stock News Headlines

November 26, 2023 | americanbankingnews.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 3.6%

November 13, 2023 | finance.yahoo.com

How Much Upside is Left in Tango Therapeutics, Inc. (TNGX)? Wall Street Analysts Think 115.31%

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 13, 2023 | finance.yahoo.com

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

November 10, 2023 | markets.businessinsider.com

Positive Outlook for Tango Therapeutics: Comprehensive Analysis of Ongoing Clinical Trials and Promising PRMT5 Inhibitors

November 10, 2023 | markets.businessinsider.com

Positive Financial Performance and Promising Drug Development Bolster Tango Therapeutics’ Buy Rating

November 9, 2023 | finance.yahoo.com

Need To Know: Analysts Are Much More Bullish On Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenues

November 8, 2023 | finance.yahoo.com

Tango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business Updates

December 3, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 8, 2023 | benzinga.com

Tango Therapeutics: Q3 Earnings Insights

November 8, 2023 | finance.yahoo.com

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

November 7, 2023 | finance.yahoo.com

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

November 5, 2023 | morningstar.com

Tango Therapeutics Inc TNGX

October 23, 2023 | seekingalpha.com

Circling Bank On Tango Therapeutics

October 18, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Prophase Labs (PRPH), Tango Therapeutics (TNGX)

October 17, 2023 | markets.businessinsider.com

Unjustified Market Concerns over PRMT5 Efficacy and Potential of TNGX Shares: A Buy Rating Analysis

October 13, 2023 | msn.com

Tango Therapeutics stock plunges amid data release for Amgen PRMT5 drug

October 13, 2023 | msn.com

Tango Therapeutics stock plunges amid Amgen PRMT5 drug data (update)

October 9, 2023 | finance.yahoo.com

What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing'

October 9, 2023 | msn.com

Why Shares of Tango Therapeutics Are Dropping Monday

September 18, 2023 | finance.yahoo.com

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 14, 2023 | msn.com

Why Shares of Tango Therapeutics Climbed This Week

September 6, 2023 | finance.yahoo.com

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

September 5, 2023 | finance.yahoo.com

Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 2, 2023 | fool.com

Tango Therapeutics (NASDAQ: TNGX)

August 31, 2023 | msn.com

Tango Therapeutics (TNGX) Price Target Increased by 10.75% to 17.17

August 30, 2023 | finanznachrichten.de

Tango Therapeutics, Inc.: Tango Therapeutics Announces Updates to Its Board of Directors

See More Headlines

Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/03/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/25/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TNGX
CUSIP: N/A
CIK: 1819133
Web: www.tangotx.com
Phone: 857-320-4900
Fax: N/A
Employees: 110
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.00
High Stock Price Target: $16.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +106.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-108,180,000.00
Net Margins: -266.73%
Pretax Margin: -266.36%
Return on Equity: -41.41%
Return on Assets: -24.28%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.54
Quick Ratio: 8.54

Sales & Book Value

Annual Sales: $24.86 million
Price / Sales: 31.84
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.71 per share
Price / Book: 2.86

Miscellaneous

Outstanding Shares: 101,990,000
Free Float: 95,667,000
Market Cap: $791.44 million
Optionable: Not Optionable
Beta: 0.86

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Barbara L. Weber M.D. (Age 66)
President, CEO & Director
Comp: $941.16k
Ms. Daniella Beckman CPA (Age 44)
Chief Financial Officer
Comp: $619.13k
Dr. Alan Ashworth FRS (Age 62)
Ph.D., Founder & Member of Scientific Advisory Board
Dr. Levi Garraway M.D. (Age 54)
Ph.D., Founder
Dr. William G. Kaelin Jr. (Age 65)
M.D., Founder & Member of Scientific Advisory Board
Dr. Timothy K. Lu M.D. (Age 42)
Ph.D., Founder
Dr. Antoni Ribas M.D. (Age 56)
Ph.D., Founder & Member of Scientific Advisory Board
Mr. Jannik N. Andersen Ph.D.
Chief Scientific Officer
Mr. Douglas J. Barry Esq. (Age 53)
J.D., General Counsel, Chief Compliance Officer & Corporate Secretary
Mr. John C. Ross M.S.
Vice President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TNGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Tango Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNGX shares.
View TNGX analyst ratings or view top-rated stocks.
What is Tango Therapeutics' stock price target for 2024?: 1 Wall Street research analysts have issued 1 year price objectives for Tango Therapeutics' shares. Their TNGX share price targets range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next year. This suggests a possible upside of 106.2% from the stock's current price.
View analysts price targets for TNGX or view top-rated stocks among Wall Street analysts.
How have TNGX shares performed in 2023?: Tango Therapeutics' stock was trading at $7.25 on January 1st, 2023. Since then, TNGX shares have increased by 7.0% and is now trading at $7.76.
View the best growth stocks for 2023 here.
When is Tango Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our TNGX earnings forecast.

How were Tango Therapeutics' earnings last quarter?: Tango Therapeutics, Inc. (NASDAQ:TNGX) posted its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.11. The firm earned $10.73 million during the quarter, compared to the consensus estimate of $8.05 million. Tango Therapeutics had a negative net margin of 266.73% and a negative trailing twelve-month return on equity of 41.41%.
What ETF holds Tango Therapeutics' stock ?: Range Cancer Therapeutics ETF holds 34,808 shares of TNGX stock, representing 1.18% of its portfolio.
Who are Tango Therapeutics' major shareholders?: Tango Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (11.42%), Adage Capital Partners GP L.L.C. (1.72%), Deerfield Management Company L.P. Series C (0.78%), Invesco Ltd. (0.76%), Northern Trust Corp (0.39%) and Charles Schwab Investment Management Inc. (0.36%). Insiders that own company stock include Adam Crystal and Boxer Capital, Llc.
View institutional ownership trends.
How do I buy shares of Tango Therapeutics?: Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TNGX) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial